JMJD1A, H3K9me1, H3K9me2 and ADM expression as prognostic markers in oral and oropharyngeal squamous cell carcinoma

Imagem de Miniatura
Arquivos
art_MAIA_JMJD1A_H3K9me1_H3K9me2_and_ADM_expression_as_prognostic_2018.PDF (10.8 MB)
Citações na Scopus
21
Tipo de produção
article
Data de publicação
2018
Editora
PUBLIC LIBRARY SCIENCE
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
MAIA, Lucas de Lima
PETERLE, Gabriela Tonini
SANTOS, Marcelo dos
TRIVILIN, Leonardo Oliveira
MENDES, Suzanny Oliveira
OLIVEIRA, Mayara Mota de
SANTOS, Joaquim Gasparini dos
STUR, Elaine
AGOSTINI, Lidiane Pignaton
COUTO, Cinthia Vidal Monteiro da Silva
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
PLOS ONE, v.13, n.3, article ID e0194884, 16p, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Aims Jumonji Domain-Containing 1 A (JMJD1A) protein promotes demethylation of histones, especially at lysin-9 of di-methylated histone H3 (H3K9me2) or mono-methylated (H3K9me1). Increased levels of H3 histone methylation at lysin-9 (H3K9) is related to tumor suppressor gene silencing. JMJD1A gene target Adrenomeduline (ADM) has shown to promote cell growth and tumorigenesis. JMJD1A and ADM expression, as well as H3K9 methylation level have been related with development risk and prognosis of several tumor types. Methods and results We aimed to evaluate JMJD1A, ADM, H3K9me1 and H3K9me2expression in paraffin embedded tissue microarrays from 84 oral and oropharyngeal squamous cell carcinoma samples through immunohistochemistry analysis. Our results showed that nuclear JMJD1A expression was related to lymph node metastasis risk. In addition, JMJD1A cytoplasmic expression was an independent risk marker for advanced tumor stages. H3K9me1 cytoplasmic expression was associated with reduced disease-specific death risk. Furthermore, high H3K9me2 nuclear expression was associated with worse specific-disease and disease-free survival. Finally, high ADM cytoplasmic expression was an independent marker of lymph node metastasis risk. Conclusion JMJD1A, H3K9me1/2 and ADM expression may be predictor markers of progression and prognosis in oral and oropharynx cancer patients, as well as putative therapeutic targets.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/27093
Referências
  1. Amar A, 2013, BRAZ J OTORHINOLAR, V79, P734, DOI 10.5935/1808-8694.20130134
  2. [Anonymous], 1978, PLOS ONE
  3. Baranello C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040678
  4. Bauman JE, 2012, CURR OPIN ONCOL, V24, P235, DOI 10.1097/CCO.0b013e3283517920
  5. Benard A, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-531
  6. Bono P, 2004, CLIN CANCER RES, V10, P7144, DOI 10.1158/1078-0432.CCR-03-0826
  7. Bredell MG, 2016, ONCOTARGET, V7, P50781, DOI 10.18632/oncotarget.9549
  8. Cajaiba MM, 2006, PEDIATR DEVEL PATHOL, V9, P196, DOI 10.2350/05-12-0002.1
  9. Chakrabarti KR, 2015, ONCOTARGET, V6, P36292, DOI 10.18632/oncotarget.5345
  10. Dambacher S, 2013, CELL CYCLE, V12, P2925, DOI 10.4161/cc.26179
  11. dos Santos M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045228
  12. Du ZM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019137
  13. Fan L, 2016, ONCOGENE, V35, P2441, DOI 10.1038/onc.2015.309
  14. Galli P, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-137
  15. Gao YQ, 2016, ONCOTARGET, V7, P63374, DOI 10.18632/oncotarget.11463
  16. Guo X, 2011, NEOPLASMA, V58, P153, DOI 10.4149/neo_2011_02_153
  17. Harris AL, 2004, NAT REV CANCER, V2, P38
  18. Hedvat CV, 2002, HUM PATHOL, V33, P968, DOI 10.1053/hupa.2002.127438
  19. Hsu FD, 2002, MODERN PATHOL, V15, P1374, DOI 10.1097/01.MP.0000039571.02827.CE
  20. Karpinich NO, 2013, FASEB J, V27, P590, DOI 10.1096/fj.12-214080
  21. Kasioulis I, 2014, MOL BIOL CELL, V25, P1216, DOI 10.1091/mbc.E13-08-0471
  22. Kaukonen R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12237
  23. Keleg S, 2007, INT J CANCER, V121, P21, DOI 10.1002/ijc.22596
  24. Krieg AJ, 2010, MOL CELL BIOL, V30, P344, DOI 10.1128/MCB.00444-09
  25. Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982
  26. Li MQ, 2015, ONCOL LETT, V10, P1003, DOI 10.3892/ol.2015.3278
  27. Lim S, 2010, INT J CANCER, V127, P1991, DOI 10.1002/ijc.25538
  28. Liu J, 2016, ONCOTARGET, V7, P85151, DOI 10.18632/oncotarget.13208
  29. Muller-Tidow C, 2010, BLOOD, V116, P3564, DOI 10.1182/blood-2009-09-240978
  30. OCHOACALLEJERO L, 2017, SMALL MOL REL ADR, V7, DOI 10.1038/S41598-017-17573-X
  31. Oehler MK, 2003, BRIT J CANCER, V89, P1927, DOI 10.1038/sj.bjc.6601397
  32. Park SJ, 2013, BIOCHEM BIOPH RES CO, V434, P722, DOI 10.1016/j.bbrc.2013.03.091
  33. Park YS, 2008, ANN SURG ONCOL, V15, P1968, DOI 10.1245/s10434-008-9927-9
  34. Ponnaluri VKC, 2011, BIOCHEM BIOPH RES CO, V415, P373, DOI 10.1016/j.bbrc.2011.10.075
  35. Puram SV, 2015, HEMATOL ONCOL CLIN N, V29, P971, DOI 10.1016/j.hoc.2015.07.003
  36. Rimm DL, 2001, EXP MOL PATHOL, V70, P255, DOI 10.1006/exmp.2001.2363
  37. Rogenhofer S, 2012, ANTICANCER RES, V32, P879
  38. Sobin L, 2009, TNM CLASSIFICATION M
  39. Soini Y, 2000, BRIT J CANCER, V83, P880, DOI 10.1054/bjoc.2000.1384
  40. Song JS, 2012, PATHOL INT, V62, P182, DOI 10.1111/j.1440-1827.2011.02776.x
  41. Uemura M, 2010, CLIN CANCER RES, V16, P4636, DOI 10.1158/1078-0432.CCR-10-0407
  42. Vavilala DT, 2012, BIOCHEM BIOPH RES CO, V422, P369, DOI 10.1016/j.bbrc.2012.04.143
  43. Wellmann S, 2008, BIOCHEM BIOPH RES CO, V372, P892, DOI 10.1016/j.bbrc.2008.05.150
  44. Xia RH, 2013, ARCH PATHOL LAB MED, V137, P1761, DOI 10.5858/arpa.2012-0704-OA
  45. Yang HY, 2015, INT J CLIN EXP PATHO, V8, P11092
  46. Yang J, 2009, ANN NY ACAD SCI, V1177, P185, DOI 10.1111/j.1749-6632.2009.05027.x
  47. Zhang CJ, 2010, J HEPATOL, V53, P889, DOI 10.1016/j.jhep.2010.05.012

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - ODS/03